ATE491728T1 - Rekombinante anti-cd64-eta' immunotoxine - Google Patents

Rekombinante anti-cd64-eta' immunotoxine

Info

Publication number
ATE491728T1
ATE491728T1 AT04819218T AT04819218T ATE491728T1 AT E491728 T1 ATE491728 T1 AT E491728T1 AT 04819218 T AT04819218 T AT 04819218T AT 04819218 T AT04819218 T AT 04819218T AT E491728 T1 ATE491728 T1 AT E491728T1
Authority
AT
Austria
Prior art keywords
vectors
diseases
further relates
complex
complex according
Prior art date
Application number
AT04819218T
Other languages
English (en)
Inventor
Michael Huhn
Rainer Fischer
Mehmet Kemal Tur
Theo Thepen
Stefan Barth
Original Assignee
Fraunhofer Ges Forschung
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fraunhofer Ges Forschung filed Critical Fraunhofer Ges Forschung
Application granted granted Critical
Publication of ATE491728T1 publication Critical patent/ATE491728T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Botany (AREA)
  • Cell Biology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT04819218T 2003-11-26 2004-11-25 Rekombinante anti-cd64-eta' immunotoxine ATE491728T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03027161 2003-11-26
PCT/EP2004/013374 WO2005052007A1 (en) 2003-11-26 2004-11-25 Recombinant anti-cd64-immunotoxins

Publications (1)

Publication Number Publication Date
ATE491728T1 true ATE491728T1 (de) 2011-01-15

Family

ID=34626377

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04819218T ATE491728T1 (de) 2003-11-26 2004-11-25 Rekombinante anti-cd64-eta' immunotoxine

Country Status (8)

Country Link
EP (1) EP1694709B1 (de)
AT (1) ATE491728T1 (de)
DE (1) DE602004030617D1 (de)
DK (1) DK1694709T3 (de)
ES (1) ES2358022T3 (de)
PL (1) PL1694709T3 (de)
PT (1) PT1694709E (de)
WO (1) WO2005052007A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2215247T3 (en) * 2007-11-13 2014-12-08 Scripps Research Inst Preparation of a fusion of cytotoxic antibody toxin into eukaryotic algae
KR20140033391A (ko) 2011-06-09 2014-03-18 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 면역원성이 보다 낮은 t 세포 및/또는 b 세포 에피토프를 갖는 슈도모나스 외독소 a
EP3301110A1 (de) 2011-09-16 2018-04-04 The USA, as represented by The Secretary, Department of Health and Human Services Pseudomonas exotoxin a mit weniger immunogenen b-zellepitopen
JP2017510577A (ja) * 2014-03-26 2017-04-13 フラウンホーファ−ゲゼルシャフト ツァー フォルデルング デア アンゲバンデン フォルシュンク エー． ファオ．Ｆｒａｕｎｈｏｆｅｒ−Ｇｅｓｅｌｌｓｃｈａｆｔ Ｚｕｒ Ｆｏｒｄｅｒｕｎｇ Ｄｅｒ Ａｎｇｅｗａｎｄｔｅｎ Ｆｏｒｓｃｈｕｎｇ Ｅ． Ｖ． 抗ＴＮＦ−α抗体療法の賦活剤としてのＣＤ６４ブロック剤の使用法
BR112017014616A2 (pt) 2015-01-21 2018-02-06 Fraunhofer Ges Forschung imunotoxina para o uso no tratamento de leishmaniose
WO2025128434A1 (en) 2023-12-14 2025-06-19 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for the treatment of ven/aza resistant acute myeloid leukemia
CN118370830B (zh) * 2024-06-25 2024-10-11 中国人民解放军军事科学院军事医学研究院 与高亲和力受体Fcgr1相关的生物材料的应用及缓解辐射性骨损伤的药物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000028050A1 (de) * 1998-11-07 2000-05-18 Bitop Gesellschaft Für Biotechnische Optimierung Mbh Verfahren zur expression rekombinanter proteine unter ausnutzung der wirkung von stress und stressantwortmechanismen in gegenwart kompatibler solute
ATE372130T1 (de) * 2000-04-22 2007-09-15 Pharmedartis Gmbh Apoptotika
GB0102145D0 (en) * 2001-01-26 2001-03-14 Scancell Ltd Substances

Also Published As

Publication number Publication date
PT1694709E (pt) 2011-03-17
ES2358022T3 (es) 2011-05-04
DK1694709T3 (da) 2011-04-04
PL1694709T3 (pl) 2011-05-31
DE602004030617D1 (de) 2011-01-27
WO2005052007A1 (en) 2005-06-09
EP1694709B1 (de) 2010-12-15
EP1694709A1 (de) 2006-08-30

Similar Documents

Publication Publication Date Title
MX2011007582A (es) Nuevas formulaciones estables de proteina de fusion recombinante de albumina humana-factor humano de estimulacion de colonias de granulocitos.
WO2021064137A3 (en) Multi-specific binding proteins for cancer treatment
EP3211001A3 (de) Superagonisten und antagonisten von interleukin-2
EP1778842B8 (de) Zusammensetzungen und verfahren zur verwendung von mgd-cdf zur krankheitsbehandlung
WO2005086798A3 (en) Improved interleukin-2 muteins
DE69922933D1 (de) Anwendungen für humane nicht autologe, mesenchymale stammzellen
SG153832A1 (en) Stable protein formulations
AU6912294A (en) Immunotoxins comprising ribosome-inactivating proteins
WO2022256500A3 (en) Dll3 targeting trispecific proteins and methods of use
WO2020186207A8 (en) Non-viral dna vectors and uses thereof for expressing fviii therapeutics
TNSN06059A1 (en) Use of polypeptides of the cupredoxin family in cancer therapy
WO2008108808A3 (en) Complexes derived from heterohybrid cells and uses thereof
DE602004030617D1 (de) Rekombinante anti-cd64-eta' immunotoxine
MX2025007855A (es) Proteina triespecifica dirigida a trop2 para el tratamiento del cancer
TNSN04235A1 (en) Compositions for therapeutic use comprising a vitamin, a metal salt and insulin or a growth hormone
Gazitt et al. Expression of adhesion molecules on CD34+ cells in peripheral blood of non-Hodgkin's lymphoma patients mobilized with different growth factors
AU2003260452A1 (en) Use of granzyme b as an hsp70/hsp70 peptide dependent inducer of apoptosis in tumor cells
AU6450098A (en) Butyrate prodrugs derived from lactic acid
PL363501A1 (en) Modified granulocyte colony stimulating factor (g-csf) with reduced immunogenicity
GR3035899T3 (en) Butyrate prodrugs of lactic acid
WO2000006735A8 (en) Interferon alpha hybrids
JP2003521439A5 (de)
WO2002079222A3 (en) Fusion proteins for specific treatment of cancer and auto-immune diseases
WO2008038296A3 (en) Recombinant calcitonin fused to interleukin-2
ATE315406T1 (de) Semi-allogene antitumor-vakzine mit hla-haplo- identischen antigen-präsentierenden zellen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties